Menu
Menu
Glenmark Pharmaceuticals has launched its Lacosamide Oral Solution, a bioequivalent to Vimpat® Oral Solution, offering a more affordable treatment option for partial-onset seizures. This new product enhances access to epilepsy care, with the same therapeutic efficacy as the branded version, making it a valuable option for patients and healthcare providers.